Abstract
Purpose :
To investigate the increase in intraocular pressure (IOP) following intravitreal injections of preservative free triamcinolone acetonide (TRIA) .
Methods :
The electronic medical record of a large single-specialty retina practice, Retina Associates of Cleveland, Inc. was queried for patients administered intravitreal TRIA injections. The Institutional Review Board granted this study a waiver of authorization. IOP was measured at the initial, subsequent, and final visit using a Goldmann applanation or tonopen. The change in eye pressure was observed in comparison to the baseline IOP. The data was analyzed on a stratified response basis, comparing stratified change of 5mmHg and 10mmHg, as well as exceeding the 21mmHg mark in IOP for those whose pressure was below that threshold prior to treatment.
Results :
There were 141 participants identified for inclusion in this study. Overall, 27 (19.1%) patients had an IOP increase from baseline that is greater than 5mmHg and 4 (2.8%) with an increase that is greater than 10mmHg. A total of 136 (96.4%) of the patients had IOP at or below 21mmHg at the first visit. Of these, 16 (11.8%) had eye pressure that exceeded 21mmHg following at least one intravitreal TRIA injection.
Conclusions :
Intravitreal injections of preservative free triamcinolone acetonide has some incidence of increased IOP among participants that were administered the treatment in this study. An increase of at least 5mmHg was shown in 19.1% of patients and 2.8% showed and increase of 10mmHg or greater. Additionally, 11.8% had their pressure increase to above 21mmHg following the treatment.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.